Metropolis Healthcare
1,963.90
-41.90(-2.09%)
Market Cap₹10,391.50 Cr
PE Ratio63.88
Company Performance:
1D-2.09%
1M-6.81%
6M+15.82%
1Y-7.01%
5Y-0.24%
View Company Insightsright
More news about Metropolis Healthcare
18Sept 25
Metropolis Healthcare Completes Acquisition of Ambika Pathology Laboratory
Metropolis Healthcare Limited has finalized the acquisition of Dr. RS Patil's Ambika Pathology Laboratory, effective September 18. The acquisition, executed as a going concern under a Business Transfer Agreement, includes deferred consideration terms. Ambika Pathology's operations have been integrated into Metropolis Healthcare's business structure. The company disclosed the acquisition details to stock exchanges in compliance with SEBI regulations.
16Sept 25
Metropolis Healthcare Launches Wholly Owned Healthcare Technology Subsidiary
Metropolis Healthcare Limited has incorporated a new wholly owned subsidiary, Metropolis Quality Solutions Private Limited, on September 15, 2023. The subsidiary will focus on healthcare technology, developing and dealing in tech-driven products and services. Metropolis Healthcare has subscribed to 10,000 equity shares at INR 10 each, maintaining 100% ownership. This strategic move aims to diversify offerings and capture new market segments in the healthcare ecosystem.
07Aug 25
Metropolis Healthcare Expands Footprint with Acquisition of Kolhapur's Ambika Pathology
Metropolis Healthcare Limited is set to acquire Dr. RS Patil's Ambika Pathology Laboratory in Kolhapur, Maharashtra for INR 17 crores. The acquisition, structured as a Business Transfer Agreement, includes the entire business as a going concern. Ambika Pathology, established in 1995, is NABL accredited with 12 patient touch points and reported revenues of INR 7.96 crore in FY 2024-25. This strategic move aims to strengthen Metropolis's presence in Western Maharashtra, establish a mini reference laboratory for surrounding districts, and enhance overall profitability in the region.
07Jul 25
Metropolis Healthcare Sees Robust Q1 Revenue Growth, Specialty Segment Shines
Metropolis Healthcare, a leading diagnostic services provider, has reported impressive Q1 financial results. The company's overall revenue increased by approximately 23% year-over-year. The specialty revenues segment showed exceptional performance, growing by over 35% compared to the same period last year. This strong growth across business segments, particularly in specialty services, indicates Metropolis Healthcare's expanding market presence and successful strategic focus on high-value diagnostic offerings.
04Jul 25
Metropolis Healthcare: Q1 Revenue Surges 23% YoY, Specialty Segment Shines
Metropolis Healthcare announced impressive Q1 financial results, with overall revenue growth of 23% year-over-year. The specialty segment showed exceptional performance, with a 35% increase in revenue. Other highlights include 13% revenue growth excluding acquisitions, 15% B2C revenue growth, and 20% growth in the TruHealth Wellness segment. The company's Core Diagnostics moved to positive margins, EBITDA improved quarter-over-quarter, and Metropolis remains debt-free.
14May 25
Metropolis Healthcare Reports Mixed Q4 FY23 Results with Profit Decline and Revenue Growth
Metropolis Healthcare's Q4 FY23 results show a 20.05% year-over-year decline in consolidated net profit to ₹291.00 crore, down from ₹364.00 crore in Q4 FY22. However, revenue increased by 4.23% to ₹345.00 crore from ₹331.00 crore in the same period last year. Compared to Q3 FY23, net profit decreased from ₹314.00 crore to ₹291.00 crore in Q4 FY23.
13May 25
Metropolis Healthcare: Q4 Profit Dips 19%, Revenue Rises 4%
Metropolis Healthcare reported Q4 FY25 results with mixed performance. Revenue increased 4.3% YoY to ₹345.30 crore, but profitability declined. EBITDA fell 22% to ₹62.30 crore, and net profit decreased 19.4% to ₹29.00 crore. Full-year highlights include 6% growth in patient volume, 7% in test volume, 17% in B2C revenue, and 12% in B2B revenue. The TruHealth portfolio showed strong revenue growth of 24%.
05May 25
Metropolis Healthcare to Announce Q4 FY2023 Results on May 13
Metropolis Healthcare Ltd., a leading Indian diagnostic services provider, will release its Q4 financial results for FY2022-23 on May 13, 2023. The announcement will offer insights into the company's performance for the quarter ending March 31, 2023, and potentially the entire fiscal year. Key financial metrics such as revenue, operating profit, net profit, and EPS are expected to be disclosed, providing valuable information for investors and analysts about the company's recent performance and position in the competitive diagnostics sector.
08Apr 25
Metropolis Healthcare Expands Footprint in North India with Strategic Acquisition in Dehradun
Metropolis Healthcare's subsidiary is set to acquire Dr. Ahujas' Pathology and Imaging Centre in Dehradun, Uttarakhand for ₹35 crore. The acquisition, expected to complete within 45 days, aims to strengthen Metropolis's presence in North India. This strategic move aligns with the company's expansion plans, enhancing its diagnostic capabilities in the region and capitalizing on the growing healthcare needs in tier-2 cities.
07Apr 25
Metropolis Healthcare Expands North India Presence with ₹35.01 Crore Acquisition of Dehradun's DAPIC
Metropolis Healthcare's subsidiary has acquired Dr. Ahujas' Pathology and Imaging Centre (DAPIC) in Dehradun for ₹35.01 crore in an all-cash deal. DAPIC, founded in 1990, is a leading diagnostic chain in Uttarakhand with NABL and NABH accredited labs. This acquisition is part of Metropolis' 'String of Pearls' strategy to expand in North India, increasing their revenue contribution from the region to 14-15%. The deal positions Metropolis as the second-largest diagnostic chain in Uttarakhand's ₹500 crore market.
09Mar 25
Metropolis Healthcare Expands North India Footprint with Strategic Acquisition
Metropolis Healthcare announces plans to acquire Scientific Pathology, an Agra-based diagnostic service provider, for a valuation between Rs 55 crore and Rs 83 crore. The deal, expected to close by March-end, aims to strengthen Metropolis' presence in Western Uttar Pradesh and North India. This strategic move follows the company's recent acquisition of Delhi-based Core Diagnostics, aligning with the ongoing consolidation trend in India's diagnostic services sector.
03Mar 25
Metropolis Healthcare Expands Footprint in Western UP with Strategic Acquisition
Metropolis Healthcare's subsidiary is acquiring Agra-based Scientific Pathology for ₹55-83 crore, strengthening its presence in Western Uttar Pradesh. The deal involves acquiring all labs and collection centers of Scientific Pathology in Agra and nearby towns. This move aims to establish Agra as a regional reference lab, accelerate B2C expansion, and enhance access to advanced diagnostics in the region. Scientific Pathology, founded in 1984, has a strong B2C focus with 90% revenue from walk-in patients and a FY24 turnover of ₹26 crore.
Metropolis Healthcare
1,963.90
-41.90
(-2.09%)
1 Year Returns:-7.01%
Industry Peers
Dr. Lal Path Labs
3,096.70
(-0.36%)
Vijaya Diagnostic Centre
1,023.60
(+0.55%)
Metropolis Healthcare
1,963.90
(-2.09%)
Thyrocare Technologies
1,391.10
(+5.05%)
Krsnaa Diagnostics
724.30
(-3.86%)
Suraksha Diagnostic
319.65
(-1.59%)
3B BlackBio DX
1,327.50
(+0.24%)
Sastasundar Ventures
289.65
(-0.07%)
Choksi Laboratories
142.25
(-0.18%)